21 stories mentioning KRX:207940Updated 8d ago
Every FINWIRES story that references KRX:207940, newest first.
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
Samsung Biologics (KRX:207940) signed a contract worth 350.8 billion Korean won to provide contract manufacturing services to an undisclosed EU-based pharmaceutical company.The contract runs from July 22, 2026, to Dec. 31, 2033, according to a Thursday filing with the Korea Exchange.
South Korean shares gained marginally on technology stocks' gains after hawkish comments from Federal Reserve Chair Kevin Warsh dragged markets lower earlier in the day. Major market movers Samsung Electronics (KRX:005930) and SK Hynix (KRX:000660) added over 1% at market close.The Korea Composite Stock Price Index, or Kospi, increased by 31.14 points, or 0.5%, to close at 6,820.02. The Kosdaq fell by 4.12 points, or 0.5%, to close at 834.29.In economic news, South Korea's all industry production index, which measures output across the mining, manufacturing, services and construction sectors, was steady in July from a month earlier, according to data released by Statistics Korea on Monday.The index compared with a 2.4% increase in June and stood at 120.2 points based on a 2020 benchmark of 100.On an annual basis, the all-industry production index rose 3.1%, softer than the 4.4% growth in the previous month.In corporate news, Samsung Biologics (KRX:207940) said its Switzerland-based unit, Samsung Peptide, has published the prospectus for its public tender offer for PolyPeptide Group, according to a Monday release.The offer includes 44.31 Swiss francs in cash per PolyPeptide share, implying an equity value of about 1.46 billion francs, and represents a 40% premium to the unaffected share price.The offer is expected to run between Sept. 15 and Oct. 12, subject to a minimum acceptance threshold, and the largest individual shareholder, Draupnir Holding, with about a 55.65% stake, has committed to tendering all its shares.Shares of Samsung Biologics rose more than 2% at market close.In other news, Samsung Heavy Industries (KRX:010140) secured a 444.5 billion won contract to build two container ships for an unnamed African buyer, according to a filing with the Korean bourse on Monday.The contract is valid from Aug. 28, 2026, to Dec. 27, 2028. Payment will be made as construction progresses, the filing said.Shares of Samsung Heavy Industries fell more than 1% at market close.
Samsung Biologics (KRX:207940) said its Switzerland-based unit, Samsung Peptide, has published the prospectus for its public tender offer for PolyPeptide Group, according to a Monday release.The offer includes 44.31 Swiss francs in cash per PolyPeptide share, implying an equity value of about 1.46 billion francs, and represents a 40% premium to the unaffected share price.The offer is expected to run between Sept. 15 and Oct. 12, subject to a minimum acceptance threshold, and the largest individual shareholder, Draupnir Holding, with about a 55.65% stake, has committed to tendering all its shares.
South Korean shares closed lower on Friday, snapping a three-day winning streak as investors sold technology heavyweights amid external uncertainties, including concerns over the Trump administration considering a new round of sweeping tariffs on semiconductors.Shares of major market movers Samsung Electronics (KRX:005930) and SK Hynix (KRX:000660) fell over 3% and 4%, respectively.The Korea Composite Stock Price Index, or Kospi, decreased by 123.49 points, or 1.8%, to close at 6,788.88. The Kosdaq rose by 0.76 points, or 0.09%, to close at 838.41.In corporate news, Samsung Biologics (KRX:207940) plans to issue 2.27 million new common shares at a par value of 2,500 won per share through a general public offering of forfeited shares after shareholder allotment, bringing the total value of the allotment to 5.68 billion won.Funds raised via the issuance will be used primarily to acquire securities issued by other corporations, with 294.8 billion won allocated for facility investment, according to a Friday filing with the Korea Exchange.Shares of Samsung Biologics fell nearly 7% at market close.In other news, Kyobo Securities (KRX:030610) has increased its borrowings by 2 trillion won, according to a Thursday filing with the Korea Exchange.The securities company carried out the transaction by increasing the issuance limit of commercial paper and short-term bonds to 4 trillion won from 2 trillion won.The additional borrowings will support an increase in the company's operating funds.Shares of Kyobo Securities rose nearly 1% at market close.
Samsung Biologics (KRX:207940) plans to issue 2.27 million new common shares at a par value of 2,500 won per share through a general public offering of forfeited shares after shareholder allotment, bringing the total value of the allotment to 5.68 billion won.Funds raised via the issuance will be used primarily to acquire securities issued by other corporations, with 294.8 billion won allocated for facility investment, according to a Friday filing with the Korea Exchange.Shares of Samsung Biologics fell nearly 6% in recent trade.
Samsung Biologics (KRX:207940) has an average rating of buy and mean price target of 2,024,695.60 won, according to analysts polled by FactSet.
Samsung Biologics (KRX:207940) posted a 29.1% year-over-year rise in second-quarter net income attributable to shareholders of the parent to 430.7 billion won from 333.6 billion won.Revenue increased 30.2% to 1.321 trillion won from 1.014 trillion won a year earlier, according to a Thursday filing with the Korea Exchange.
Samsung Biologics (KRX:207940) posted second-quarter net income attributable to shareholders of 430.7 billion won, up 29% from 333.6 billion won a year earlier, according to a Thursday filing with the Korea Exchange.The South Korean contract development and manufacturing company's sales jumped 30% year over year to 1.321 trillion won from 1.014 trillion won.Shares of Samsung Biologics rose nearly 2% in recent trade.
The acquisition of Switzerland's PolyPeptide Group by Samsung Biologics (KRX:207940) is scheduled for settlement on Nov. 30, under a cash tender offer valued at 2.706 trillion won.The board-approved plan targets 33 million shares, representing a 100% stake, according to parent Samsung C&T's (KRX:028260) bourse filing on Tuesday.The target's largest shareholder, Draupnir Holding, has already committed to tendering its 55.65% stake, though the offer hinges on a minimum tender condition of roughly two-thirds of the fully diluted share capital.
South Korean stocks plunged more than 4% on Monday as investor concerns shot up due to escalating Middle East tensions.The Korea Composite Stock Price Index, or Kospi, decreased by 304.33 points, or 4.5%, to end at 6,516.27. The Kosdaq also fell by 42.2 points, or 5.3%, to close at 749.64.The U.S. military said Monday that it carried out a ninth straight night of strikes on Iran, targeting command centers, air defenses, missile facilities and other military infrastructure, while a U.S. service member died in northern Iraq during the controlled disposal of an unexploded Iranian drone.Several locations in Bushehr, the capital of Iran's southwestern Bushehr province, were hit in an attack, the province's governor said, Mehr News Agency reported.In economic news, the per capita gross domestic product (GDP) of South Korea is estimated to increase 7.6%, or up $2,750, on-year to about $39,164 this year, Yonhap News reported Sunday, citing data from local analysts.The projected per capita GDP growth will be the strongest annual jump since the 11.5% recorded in 2021, according to the report.In corporate news, the brand value of Samsung Group, the parent group of Samsung Electronics (KRX:005930) and Samsung Biologics (KRX:207940), jumped 8.9% to $97.4 billion in 2026 from $89.4 billion in 2025, British consulting firm Brand Finance said in a Sunday report.The group ranked eighth in Brand Finance's ranking of the top 100 tech companies globally.SK Hynix (KRX:000660) rose one place to 28th, LG Corp (KRX:003550) slipped eight spots to 44th, Coupang slipped one position to 49th, and Naver (KRX:035420) moved up five places to 95th, according to the report.Shares of Samsung Electronics and SK Hynix fell nearly 4% at market close, while Samsung Biologics declined 3%. Shares of Naver fell over 2% at market close.
Samsung Biologics (KRX:207940) launched an all-cash tender offer to acquire Swiss peptide drug manufacturer PolyPeptide, expanding its contract development and manufacturing business into the fast-growing peptide therapeutics market.The South Korean biotechnology company is offering 44.31 Swiss francs in cash for each PolyPeptide share, valuing the company at about 1.46 billion francs.The offer represents a 40% premium to PolyPeptide's unaffected closing share price on April 10, before market speculation about a potential acquisition emerged.The transaction has received unanimous backing from PolyPeptide's independent and non-conflicted board members. It is also supported by the company's largest shareholder, which has irrevocably agreed to tender its about 55.65% stake."After a comprehensive review of strategic options, the Board is convinced that Samsung Biologics' offer is compelling for our shareholders, delivering an attractive cash price and immediate, certain value today," PolyPeptide Chairman Peter Wilden said.Based in Baar, Switzerland, PolyPeptide was spun off from pharmaceutical company Ferring in 1996 and has developed and manufactured more than 1,000 therapeutic peptides.The acquisition will expand Samsung Biologics' capabilities beyond antibodies and antibody-drug conjugates to include peptide-based active pharmaceutical ingredients.The move targets a rapidly growing market fueled by rising demand for treatments for obesity and diabetes, including GLP-1 therapies."This acquisition reinforces our long-term growth strategy by not only broadening our service portfolio with modality expansion into peptides, including GLP-1, but also by boosting our geographic reach and proximity further within the U.S., Europe and India," Chief Executive John Rim said.PolyPeptide operates manufacturing, research and development facilities across Sweden, Belgium, France, the United States and India, giving Samsung Biologics a broader global production network and expanding its presence in key pharmaceutical markets.The tender offer is expected to launch by the end of August and close toward the end of 2026, subject to regulatory approvals and a minimum acceptance threshold of PolyPeptide's fully diluted share capital.Following completion, Samsung Biologics intends to acquire any remaining minority shares and delist PolyPeptide from the SIX Swiss Exchange.While not directly related to the transaction, the deal comes as peptide-based medicines and ingredients face growing regulatory attention.The U.S. Food and Drug Administration's Pharmacy Compounding Advisory Committee is set to review several peptide substances for possible inclusion on the agency's bulk drug substances list at a July 23-24 meeting.
The brand value of Samsung Group, the parent group of Samsung Electronics (KRX:005930) and Samsung Biologics (KRX:207940), jumped 8.9% to $97.4 billion in 2026 from $89.4 billion in 2025, British consulting firm Brand Finance said in a Sunday report.The group ranked eighth in Brand Finance's ranking of top 100 tech companies globally.SK Hynix (KRX:000660) rose one place to 28th, LG Corp (KRX:003550) slipped eight spots to 44th, Coupang slipped one position to 49th, and Naver (KRX:035420) moved up five places to 95th, according to the report.Shares of Samsung Electronics fell more than 4%, while Samsung Biologics declined 3%. Shares of SK Hynix declined more than 4%, and those of Naver fell nearly 3%.
Samsung Biologics (KRX:207940) will wholly acquire Switzerland-based PolyPeptide Group for about 2.71 trillion won to boost the competitiveness of its peptide contract development and manufacturing organization (CDMO) business, according to a Monday filing with the Korean Exchange.The company will purchase 33.02 million shares, which is the entire issued share capital of PolyPeptide.Shares of Samsung Biologics fell nearly 2% in recent trade.
South Korean shares closed slightly lower on Monday on losses made by heavyweight technology stocks Samsung Electronics (KRX:005930) and SK Hynix (KRX:000660), shares of which fell by nearly 5% and 2%, respectively, at market close.Rising oil prices also put a strain on investor optimism amid the continued hostilities between the U.S. and Iran. Brent crude for August delivery traded at $73.21 a barrel as of 03:30 GMT, rising $1.27 higher from its level before the U.S. and Israel launched military action against Iran on Feb. 28.The benchmark Korea Composite Stock Price Index, or Kospi, marginally declined by 0.2%, or 16.56 points, to close at 8,394.65. The Kosdaq, however, rose by 8.1%, or 69.2 points, to end at 920.57.On the corporate front, the labor union of Samsung Biologics (KRX:207940) on Sunday voted to exit the Samsung Group federation, with an aim to alter the union's organizational structure, Pulse News reported Monday.The union conducted a vote from June 24 to June 28, with 2,392 of 2,479 participating members, or 96.5%, backing the proposal to quit the group federation. The proposal required a majority turnout and approval from at least two-thirds of participating members to pass, according to the report.Responding to, Samsung Biologics said the union's withdrawal from the super‑union is expected to have minimal impact, adding discussions on scheduling proposals remain ongoing, and it remains committed to operational stability and minimizing any effect on client projects.Shares of the company jumped nearly 8% at market close.In other news, HD Korea Shipbuilding & Offshore Engineering (KRX:009540) won an order for two liquefied petroleum gas (LPG) carriers from an Asia-based shipper, according to a Monday filing with the Korean Exchange.The deal is valued at 366 billion won. The shipbuilder will deliver the vessels by Dec. 31, 2029.Shares of HD Korea Shipbuilding rose over 6% at market close.
(Updates to add comment from Samsung Biologics)The labor union of Samsung Biologics (KRX:207940) on Sunday voted to exit the Samsung Group federation, with an aim to alter the union's organizational structure, Pulse News reported Monday.The union conducted a vote from June 24 to June 28, with 2,392 of 2,479 participating members, or 96.5%, backing the proposal to quit the group federation. The proposal required a majority turnout and approval from at least two-thirds of participating members to pass, according to the report.Responding to, Samsung Biologics said the union's withdrawal from the super‑union is expected to have minimal impact, adding discussions on scheduling proposals remain ongoing and it remains committed to operational stability and minimizing any effect on client projects.Shares of the company jumped nearly 8% at market close.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
The labor union of Samsung Biologics (KRX:207940) on Sunday voted to exit the Samsung Group federation, with an aim to alter the union's organizational structure, Pulse News reported Monday.The union conducted a vote from June 24 to June 28, with 2,392 of 2,479 participating members, or 96.5%, backing the proposal to quit the group federation. The proposal required a majority turnout and approval from at least two-thirds of participating members to pass, according to the report.Samsung Biologics did not immediately reply to' request for comment.Shares of the company jumped nearly 4% in recent trade.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Samsung Biologics (KRX:207940) secured a biologics contract manufacturing organization (CMO) contract from an undisclosed Asian pharmaceutical company, according to a Monday filing with the Korean Exchange.The contract is valued at 215.9 billion won and is valid until Dec. 31, 2037.Shares of Samsung Biologics rose nearly 1% in recent trade.
South Korean shares closed at a record high on Thursday, with the country's primary index surpassing the 9,000-point level for the first time ever.Investor sentiment was particularly buoyed by the US-Iran deal and the reopening of the Strait of Hormuz. In addition, the U.S. Federal Reserve's decision to keep its key rate steady in the range of 3.50%-3.75% at its latest rate-setting meeting also boosted sentiment.The benchmark Korea Composite Stock Price Index, or Kospi, increased by 2.3%, or 199.6 points, to close at 9,063.84. The Kosdaq, however, decreased by 3%, or 31.03 points, to end at 1,000.93.Thursday's gain marked the sixth straight day of gains, owing to optimism over the AI sector. Shares of market movers and chip stocks Samsung Electronics (KRX:005930) and SK Hynix (KRX:000660) rose nearly 5% and 7%, respectively.U.S. President Donald Trump and Iranian President Masoud Pezeshkian signed the Iran document on Wednesday night, the White House told the BBC.Key aspects of the deal comprise Iran's commitment not to develop a nuclear weapon, the restoration of shipping via the Strait of Hormuz with no transit fees for at least 60 days, the removal of U.S. sanctions, and an end to hostilities, including in Lebanon.In corporate news, Samsung Biologics (KRX:207940) secured a biologics contract manufacturing organization (CMO) contract from an undisclosed US-based pharmaceutical company. The contract, valued at 835.7 billion won, is valid until Dec. 31, 2031.Shares of Samsung Biologics added over 4% at market close.
Samsung Biologics (KRX:207940) secured a biologics contract manufacturing organization (CMO) contract from an undisclosed US-based pharmaceutical company, according to a Wednesday filing with the Korean Exchange.The contract, valued at 835.7 billion won, is valid until Dec. 31, 2031.Shares of Samsung Biologics added over 5% in recent trade on Thursday.
Samsung Biologics (KRX:207940) posted first-quarter net income attributable to shareholders of 469.2 billion won, up 42% from 331.3 billion won a year earlier, according to a Friday filing with the Korea Exchange.The South Korean contract development and manufacturing company's sales jumped 26% year over year to 1.257 trillion won from 999.5 billion won.Shares of Samsung Biologics rose nearly 1% at market close.
Showing 1-20 of 21
